NCT03148418
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 3
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: Child, Adult, Older Adult
Location of Metastases: 
Additional Notes: Patients must have been previously enrolled in a Genentech− and/or F. Hoffmann-La Roche Ltd-sponsored atezolizumab study 
Exclusions: 
https://ClinicalTrials.gov/show/NCT03148418